{"filing":{"accession_number":"0001654954-26-006239","cik":"0000901832","ticker":"AZN","company_name":"ASTRAZENECA PLC","form":"6-K","filing_date":"2026-06-29","report_date":null,"primary_document":"a0148k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426006239/a0148k.htm"},"events":[{"id":14398,"run_id":12818,"accession_number":"0001654954-26-006239","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces a positive Committee for Medicinal Products for Human Use (CHMP) recommendation for approval of Datroway (datopotamab deruxtecan) in the EU for first-line treatment of metastatic triple-negative breast cancer. This is a material regulatory milestone for a key oncology asset, based on Phase III trial results showing statistically significant improvements in overall survival and progression-free survival. While this is a regulatory/operational event rather than a discrete financial event, it materially affects the registrant's product pipeline and commercial prospects and would affect a reasonable investor's assessment of the company's oncology portfolio.","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-06-29","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":11812,"accession_number":"0001654954-26-006239","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces a positive Committee for Medicinal Products for Human Use (CHMP) recommendation for approval of Datroway (datopotamab deruxtecan) in the EU for first-line treatment of metastatic triple-negative breast cancer. This is a material regulatory milestone for a key oncology asset, based on Phase III trial results showing statistically significant improvements in overall survival and progression-free survival. While this is a regulatory/operational event rather than a discrete financial event, it materially affects the registrant's product pipeline and commercial prospects and would affect a reasonable investor's assessment of the company's oncology portfolio.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-29T10:07:26.757344+00:00","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-06-29"}]}